Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26599781 | 0.88 | DPP4 (0.35) | DPP4DPP8DPP9DPP7ATM | |
| SCHEMBL26599785 | 0.88 | DPP4 (0.35) | DPP4DPP8DPP9DPP7ATM | |
| SCHEMBL17207644 | 0.88 | DPP4 (0.35) | DPP4DPP8DPP9DPP7ATM | |
| SCHEMBL24456071 | 0.81 | MCHR1 (0.33) | DPP4DPP8DPP9DPP7MCHR1 | |
| SCHEMBL24629359 | 0.78 | ACHE (0.34) | DPP4DPP8DPP9DPP7BTK | |
| SCHEMBL4532414 | 0.77 | ATM (0.34) | ATMNPY5R | |
| Trifluoroacetic Acid SCHEMBL3006963 | 0.77 | GABRP (0.35) | HRH4HRH3 | |
| SCHEMBL12849690 | 0.75 | DPP4 (0.35) | DPP4DPP8DPP9DPP7ATM | |
| Trifluoroacetic Acid SCHEMBL27702554 | 0.75 | PDK1 (0.43) | HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL29936279 | 0.75 | PDK1 (0.39) | DPP4DPP8BTKHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | Asteroid Therapeutics (US) | 2025-10-28 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| WO-2023205801-A2 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | SREBF1, SREBF2, NR1H3 | DPP4 3516/4885DPP8 3541/4885DPP9 3375/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | DPP4 3516/4885DPP8 3541/4885DPP9 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.